- Home
- GSK vs CRH Comparison
GSK vs CRH Comparison
Compare GSK & CRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | CRH |
|---|---|---|
| Founded | 1715 | 1936 |
| Country | United Kingdom | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9B | 83.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GSK | CRH |
|---|---|---|
| Price | $50.64 | $128.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | N/A | ★ $131.71 |
| AVG Volume (30 Days) | 3.1M | ★ 13.1M |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.38% | 1.15% |
| EPS Growth | ★ 118.57 | 0.53 |
| EPS | 1.79 | ★ 5.01 |
| Revenue | ★ $43,237,357,842.00 | $36,901,000,000.00 |
| Revenue This Year | $6.70 | $6.72 |
| Revenue Next Year | $5.10 | $5.99 |
| P/E Ratio | $27.45 | ★ $25.63 |
| Revenue Growth | 2.73 | ★ 4.28 |
| 52 Week Low | $31.72 | $76.75 |
| 52 Week High | $49.63 | $129.28 |
Technical Indicators
Market Signals| Indicator | GSK | CRH |
|---|---|---|
| Relative Strength Index (RSI) | 67.52 | 61.56 |
| Support Level | $48.59 | $124.77 |
| Resistance Level | $49.40 | $129.28 |
| Average True Range (ATR) | 0.56 | 2.27 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 75.11 | 94.76 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About CRH CRH PLC
CRH is a global manufacturer of a range of building products used in construction projects, operating via a vertically integrated business model. The past decade has seen CRH transform into a leading building materials business, with increasing exposure to upstream building activities such as aggregates and cement. CRH's geographic footprint is mostly across developed markets. North America is CRH's largest market and accounts for 75% of EBITDA. The company is the largest producer of aggregates and asphalt in the US.